Monitored consideration of patent legislation; international intellectual property issues; general issues related to patent settlements; and all provisions of H.R. 9, the Innovation Act.
General issues related to health; and issues related to the need for research into clinical tools to diagnose and assess the severity of atopic dermatitis.
General issues related to corporate tax reform.
Duration: November 1, 2007
to
August 31, 2017
General Issues: Copyright/Patent/Trademark , Health Issues , Taxation/Internal Revenue Code , Trade (Domestic & Foreign) , Economics/Economic Development , Medical/Disease Research/Clinical Labs , Medicare/Medicaid , Law Enforcement/Crime/Criminal Justice , Financial Institutions/Investments/Securities
Spending: about $1,210,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2007: U.S. Senate, House of Representatives, U.S. Senate,, Y
Y, N
Y
Affiliated organizations: sanofi-aventus U.S. LLC
Related Foreign Entities:
sanofi-aventis SA (Paris, FRA); contribution to lobbying: $0; ownership 100%
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
3rd Quarter, 2017
PARRY, ROMANI, DECONCINI & SYMMS terminated an engagement in which they represented Sanofi US Services Inc. (formerly known as sanofi-aventis U.S. Inc.) on Oct. 6, 2017.
Original Filing: 300901892.xml
Lobbying Issues
Monitored consideration of patent legislation; international intellectual property issues; general issues related to patent settlements; and all provisions of H.R. 9, the Innovation Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
General issues related to health; and issues related to the need for research into clinical tools to diagnose and assess the severity of atopic dermatitis.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to corporate tax reform.
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2017
In Q2, PARRY, ROMANI, DECONCINI & SYMMS lobbied for Sanofi US Services Inc. (formerly known as sanofi-aventis U.S. Inc.) , earning $30,000. The report was filed on July 13, 2017.
Original Filing: 300884390.xml
Lobbying Issues
Monitored consideration of patent legislation; international intellectual property issues; general issues related to patent settlements; and all provisions of H.R. 9, the Innovation Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
General issues related to health; and issues related to the need for research into clinical tools to diagnose and assess the severity of atopic dermatitis.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to corporate tax reform.
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2017
In Q1, PARRY, ROMANI, DECONCINI & SYMMS lobbied for Sanofi US Services Inc. (formerly known as sanofi-aventis U.S. Inc.) , earning $30,000. The report was filed on April 12, 2017.
Original Filing: 300864491.xml
Lobbying Issues
Monitored consideration of patent legislation; international intellectual property issues; general issues related to patent settlements; and all provisions of H.R. 9, the Innovation Act; and S. 1137, Protecting American Talent and Entrepeneurship Act of 2015.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to the 21st Century Cures Initiative, including all provisions of H.R. 6, To accelerate the discovery, development, and delivery of 21st century cures and for other purposes (21st Century Cures Act). Issues related to the need for research into clinical tools to diagnose and assess the severity of atopic dermatitis.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to corporate tax reform.
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2016
In Q4, PARRY, ROMANI, DECONCINI & SYMMS lobbied for Sanofi US Services Inc. (formerly known as sanofi-aventis U.S. Inc.) , earning $45,000. The report was filed on Jan. 17, 2017.
Original Filing: 300847533.xml
Lobbying Issues
Monitored consideration of patent legislation; international intellectual property issues; general issues related to patent settlements; and all provisions of H.R. 9, the Innovation Act; and S. 1137, Protecting American Talent and Entrepeneurship Act of 2015.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to the 21st Century Cures Initiative, including all provisions of H.R. 6, To accelerate the discovery, development, and delivery of 21st century cures and for other purposes (21st Century Cures Act). Issues related to the need for research into clinical tools to diagnose and assess the severity of atopic dermatitis. Issues related to insulin and vaccines, no specific legislation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to corporate tax reform.
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2016
In Q3, PARRY, ROMANI, DECONCINI & SYMMS lobbied for Sanofi US Services Inc. (formerly known as sanofi-aventis U.S. Inc.) , earning $45,000. The report was filed on Oct. 14, 2016.
Original Filing: 300828128.xml
Lobbying Issues
Monitored consideration of patent legislation; international intellectual property issues; general issues related to patent settlements; and all provisions of H.R. 9, the Innovation Act; and S. 1137, Protecting American Talent and Entrepeneurship Act of 2015.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to the 21st Century Cures Initiative, including all provisions of H.R. 6, To accelerate the discovery, development, and delivery of 21st century cures and for other purposes (21st Century Cures Act). Issues related to the need for research into clinical tools to diagnose and assess the severity of atopic dermatitis.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to corporate tax reform.
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2016
In Q2, PARRY, ROMANI, DECONCINI & SYMMS lobbied for Sanofi US Services Inc. (formerly known as sanofi-aventis U.S. Inc.) , earning $40,000. The report was filed on July 19, 2016.
Original Filing: 300813954.xml
Lobbying Issues
Monitored consideration of patent legislation; international intellectual property issues; general issues related to patent settlements; and all provisions of H.R. 9, the Innovation Act; and S. 1137, Protecting American Talent and Entrepeneurship Act of 2015.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to the 21st Century Cures Initiative, including all provisions of H.R. 6, To accelerate the discovery, development, and delivery of 21st century cures and for other purposes (21st Century Cures Act). Issues related to the need for research into clinical tools to diagnose and assess the severity of atopic dermatitis.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to corporate tax reform.
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2016
In Q1, PARRY, ROMANI, DECONCINI & SYMMS lobbied for Sanofi US Services Inc. (formerly known as sanofi-aventis U.S. Inc.) , earning $30,000. The report was filed on April 19, 2016.
Original Filing: 300795222.xml
Lobbying Issues
Monitored consideration of patent legislation; international intellectual property issues; general issues related to patent settlements; and all provisions of H.R. 9, the Innovation Act; and S. 1137, Protecting American Talent and Entrepeneurship Act of 2015.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to the 21st Century Cures Initiative, including all provisions of H.R. 6, To accelerate the discovery, development, and delivery of 21st century cures and for other purposes (21st Century Cures Act). Issues related to the need for research into clinical tools to diagnose and assess the severity of atopic dermatitis.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to corporate tax reform.
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2015
In Q4, PARRY, ROMANI, DECONCINI & SYMMS lobbied for Sanofi US Services Inc. (formerly known as sanofi-aventis U.S. Inc.) , earning $30,000. The report was filed on Jan. 13, 2016.
Original Filing: 300771052.xml
Lobbying Issues
Monitored consideration of patent legislation; international intellectual property issues; general issues related to patent settlements; and all provisions of H.R. 9, the Innovation Act; and S. 1137, Protecting American Talent and Entrepeneurship Act of 2015.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to the 21st Century Cures Initiative, including all provisions of H.R. 6, To accelerate the discovery, development, and delivery of 21st century cures and for other purposes (21st Century Cures Act).
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to corporate tax reform.
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2015
In Q3, PARRY, ROMANI, DECONCINI & SYMMS lobbied for Sanofi US Services Inc. (formerly known as sanofi-aventis U.S. Inc.) , earning $30,000. The report was filed on Oct. 15, 2015.
Original Filing: 300753569.xml
Lobbying Issues
Monitored consideration of patent legislation; international intellectual property issues; general issues related to patent settlements; and all provisions of H.R. 9, the Innovation Act; and S. 1137, Protecting American Talent and Entrepeneurship Act of 2015.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to the 21st Century Cures Initiative, including all provisions of H.R. 6, To accelerate the discovery, development, and delivery of 21st century cures and for other purposes (21st Century Cures Act); education and awareness of diabetes and related treatments.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Trade Promotion Authority (TPA) including all such provisions of S.995 and H.R. 1890, Bipartisan Congressional Trade Priorities and Accountability Act of 2015 and H.R. 1314, Ensuring Tax Exempt Organizations the Right to Appeal Act (or Trade Act of 2015) and such portions of those bills as included in H.R. 2146, Defending Public Safety Employees Retirement Act and General issues related to the Trans-Pacific Partnership (TPP) and Transatlantic Trade and Investment Partnership (TTIP) negotiations.
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2015
In Q2, PARRY, ROMANI, DECONCINI & SYMMS lobbied for Sanofi US Services Inc. (formerly known as sanofi-aventis U.S. Inc.) , earning $30,000. The report was filed on July 16, 2015.
Original Filing: 300736294.xml
Lobbying Issues
Monitored consideration of patent legislation; international intellectual property issues; general issues related to patent settlements; and all provisions of H.R. 9, the Innovation Act; and S. 1137, Protecting American Talent and Entrepeneurship Act of 2015.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to the 21st Century Cures Initiative, including all provisions of H.R. 6, To accelerate the discovery, development, and delivery of 21st century cures and for other purposes (21st Century Cures Act); education and awareness of diabetes and related treatments; and issues related to the need for research into clinical tools to diagnose and assess the severity of atopic dermatitis.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Trade Promotion Authority (TPA) including all such provisions of S.995 and H.R. 1890, Bipartisan Congressional Trade Priorities and Accountability Act of 2015 and H.R. 1314, Ensuring Tax Exempt Organizations the Right to Appeal Act (or Trade Act of 2015) and such portions of those bills as included in H.R. 2146, Defending Public Safety Employees Retirement Act and General issues related to the Trans-Pacific Partnership (TPP) and Transatlantic Trade and Investment Partnership (TTIP) negotiations.
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2015
In Q1, PARRY, ROMANI, DECONCINI & SYMMS lobbied for Sanofi US Services Inc. (formerly known as sanofi-aventis U.S. Inc.) , earning $30,000. The report was filed on April 14, 2015.
Original Filing: 300715019.xml
Lobbying Issues
Monitored consideration of patent legislation; S. 1013, the Patent Abuse Reduction Act of 2013; S. 1612, Patent Litigation Integrity Act of 2013; and H.R. 9, the Innovation Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
General issues related to prescription drug safety and the importation of prescription drugs.
General issues regarding implementation of Public Law 111-148, Patient Protection and Affordable Care Act.
Agencies Lobbied
U.S. Senate
4th Quarter, 2014
In Q4, PARRY, ROMANI, DECONCINI & SYMMS lobbied for Sanofi US Services Inc. (formerly known as sanofi-aventis U.S. Inc.) , earning $30,000. The report was filed on Jan. 15, 2015.
Original Filing: 300696825.xml
Lobbying Issues
Monitored consideration of patent legislation; S. 1013, the Patent Abuse Reduction Act of 2013; S. 1612, Patent Litigation Integrity Act of 2013; and H.R. 3309, the Innovation Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to foreign direct investment in the U.S., including all provisions of H.R. 2052, Global Investment in American Jobs Act of 2013.
Type of Issue
Economics/Economic Development
Lobbying Issues
General issues related to prescription drug safety and the importation of prescription drugs.
General issues regarding implementation of Public Law 111-148, Patient Protection and Affordable Care Act.
Support H.R. 2985, the Combination Drug Development Incentive Act of 2013, to provide incentives for new drug development.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support H.R. 2985, the Combination Drug Development Incentive Act of 2013, to provide incentives for new drug development.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2014
PARRY, ROMANI, DECONCINI & SYMMS amended a lobbying report for representation of Sanofi US Services Inc. (formerly known as sanofi-aventis U.S. Inc.) in Q32014 on Jan. 15, 2015.
Original Filing: 300696846.xml
Lobbying Issues
Monitored consideration of patent legislation; S.1013, the Patent Abuse Reduction Act of 2013; S.1612, Patent Litigation Integrity Act of 2013; and H.R.3309, the Innovation Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
All provisions of H.R.2052, Global Investment in American Jobs Act of 2013
Type of Issue
Economics/Economic Development
Lobbying Issues
General issues related to prescription drug safety and the importation of prescription drugs.
General issues regarding implementation of Public Law 111-148, Patient protection and Affordable Care Act.
Support H.R.2985, the Combination Drug Development Incentive Act of 2013, to provide incentives for new drug development.
H.R. 4502, Stop Meth Labs and Enhance Patient Access Act of 2014.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support H.R.2985, the Combination Drug Development Incentive Act of 2013, to provide incentives for new drug development.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2014
In Q3, PARRY, ROMANI, DECONCINI & SYMMS lobbied for Sanofi US Services Inc. (formerly known as sanofi-aventis U.S. Inc.) , earning $30,000. The report was filed on Oct. 14, 2014.
Original Filing: 300676181.xml
Lobbying Issues
Monitored consideration of patent legislation; S.1013, the Patent Abuse Reduction Act of 2013; S.1612, Patent Litigation Integrity Act of 2013; and H.R.3309, the Innovation Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
All provisions of H.R.2052, Global Investment in American Jobs Act of 2013
Type of Issue
Economics/Economic Development
Lobbying Issues
General issues related to prescription drug safety and the importation of prescription drugs.
General issues regarding implementation of Public Law 111-148, Patient protection and Affordable Care Act.
Support H.R.2985, the Combination Drug Development Incentive Act of 2013, to provide incentives for new drug development.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support H.R.2985, the Combination Drug Development Incentive Act of 2013, to provide incentives for new drug development.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
2nd Quarter, 2014
In Q2, PARRY, ROMANI, DECONCINI & SYMMS lobbied for Sanofi US Services Inc. (formerly known as sanofi-aventis U.S. Inc.) , earning $30,000. The report was filed on July 15, 2014.
Original Filing: 300656618.xml
Lobbying Issues
Monitored consideration of patent legislation; S. 1013, the Patent Abuse Reduction Act of 2013; S. 1612, Patent Litigation Integrity Act of 2013; and H.R. 3309, the Innovation Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H.R. 2052 / S. 1023, Global Investment in American Jobs Act of 2013
Type of Issue
Economics/Economic Development
Lobbying Issues
General issues related to prescription drug safety and the importation of prescription drugs.
General issues regarding implementation of Public Law 111-148, Patient Protection and Affordable Care Act (ACT).
Support H.R. 2985, the Combination Drug Development Incentive Act of 2013, to provide incentives for new drug development.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support H.R. 2985, the Combination Drug Development Incentive Act of 2013, to provide incentives for new drug development.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
General issues related to changes to Medicare Part B reimbursement of prescription drugs; issues related to coverage and reimbursement issues for those who are covered by the Medicaid program and the Medicare program; including the Part D prescription drug benefit.
Agencies Lobbied
U.S. Senate
1st Quarter, 2014
In Q1, PARRY, ROMANI, DECONCINI & SYMMS lobbied for Sanofi US Services Inc. (formerly known as sanofi-aventis U.S. Inc.) , earning $30,000. The report was filed on April 18, 2014.
Original Filing: 300640823.xml
Lobbying Issues
General issues related to prescription drug safety and the importation of prescription drugs.
General issues regarding implementation of Public Law 111-148, Patient Protection and Affordable Care Act.
Support H.R. 2985, the Combination Drug Development Incentive Act of 2013, to provide incentives for new drug development.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support H.R. 2985, the Combination Drug Development Incentive Act of 2013, to provide incentives for new drug development.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
General issues related to changes to the Medicare Part B reimbursement of prescription drugs; issues related to coverage and reimbursement issues for those who are covered by the Medicaid program and the Medicare program; including the Part D prescription drug benefit.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 2052 / S. 1023, Global Investment in American Jobs Act of 2013.
Type of Issue
Economics/Economic Development
Lobbying Issues
Monitored consideration of patent legislation; S. 1013, the Patent Abuse Reduction Act of 2013; S. 1612, Patent Litigation Integrity Act of 2013; and H.R. 3309, the Innovation Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2013
In Q4, PARRY, ROMANI, DECONCINI & SYMMS lobbied for Sanofi US Services Inc. (formerly known as sanofi-aventis U.S. Inc.) , earning $30,000. The report was filed on Jan. 10, 2014.
Original Filing: 300612641.xml
Lobbying Issues
General issues related to prescription drug safety and the importation of prescription drugs.
General issues regarding implementation of Public Law 111-148, Patient Protection and Affordable Care Act.
Support H.R. 2985, the Combination Drug Development Incentive Act of 2013, to provide incentives for new drug development.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support H.R. 2985, the Combination Drug Development Incentive Act of 2013, to provide incentives for new drug development.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
General issues related to changes to the Medicare Part B reimbursement of prescription drugs; issues related to coverage and reimbursement issues for those who are covered by the Medicaid program and the Medicare program; including the Part D prescription drug benefit.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 2052 / S. 1023, Global Investment in American Jobs Act of 2013.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Economics/Economic Development
Lobbying Issues
Monitored consideration of patent legislation; S. 1013, the Patent Abuse Reduction Act of 2013; S. 1612, Patent Litigation Integrity Act of 2013; and H.R. 3309, the Innovation Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2013
In Q3, PARRY, ROMANI, DECONCINI & SYMMS lobbied for Sanofi US Services Inc. (formerly known as sanofi-aventis U.S. Inc.) , earning $30,000. The report was filed on Oct. 11, 2013.
Original Filing: 300592889.xml
Lobbying Issues
General issues related to prescription drug safety and the importation of prescription drugs.
General issues regarding implementation of Public Law 111-148, Patient Protection and Affordable Care Act.Issues related to School Access to Emergency Epinephrine.
Support H.R. 2985, the Combination Drug Development Incentive Act of 2013, to provide incentives for new drug development.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support H.R. 2985, the Combination Drug Development Incentive Act of 2013, to provide incentives for new drug development.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
General issues related to changes to the Medicare Part B reimbursement of prescription drugs; issues related to coverage and reimbursement issues for those who are covered by the Medicaid program and the Medicare program; including the Part D prescription drug benefit.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 2052 / S. 1023, Global Investment in American Jobs Act of 2013.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Economics/Economic Development
2nd Quarter, 2013
In Q2, PARRY, ROMANI, DECONCINI & SYMMS lobbied for Sanofi US Services Inc. (formerly known as sanofi-aventis U.S. Inc.) , earning $30,000. The report was filed on July 17, 2013.
Original Filing: 300574177.xml
Lobbying Issues
General issues related to prescription drug safety.
General issues regarding implementation of Public Law 111-148, Patient Protection and Affordable Care Act.
Issues related to School Access to Emergency Epinephrine.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to changes to the Medicare Part B reimbursement of prescription drugs; issues related to coverage and reimbursement issues for those who are covered by the Medicaid program and the Medicare program; including the Part D prescription drug benefit.
Agencies Lobbied
U.S. Senate
1st Quarter, 2013
In Q1, PARRY, ROMANI, DECONCINI & SYMMS lobbied for Sanofi US Services Inc. (formerly known as sanofi-aventis U.S. Inc.) , earning $30,000. The report was filed on April 17, 2013.
Original Filing: 300552272.xml
Lobbying Issues
General issues related to prescription drug safety and the importation of prescription drugs.
General issues regarding implementation of Public Law 111-148, Patient Protection and Affordable Care Act.
Issues related to School Access to Emergency Epinephrine.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to changes to the Medicare Part B reimbursement of prescription drugs; issues related to coverage and reimbursement issues for those who are covered by the Medicaid program and the Medicare program; including the Part D prescription drug benefit.
Agencies Lobbied
U.S. Senate
4th Quarter, 2012
In Q4, PARRY, ROMANI, DECONCINI & SYMMS lobbied for Sanofi US Services Inc. (formerly known as sanofi-aventis U.S. Inc.) , earning $30,000. The report was filed on Jan. 15, 2013.
Original Filing: 300529146.xml
Lobbying Issues
Opposed efforts to preclude settlements in patent litigation.
H.R. 3995, Protecting Consumer Access to Generic Drugs Act of 2012
S. 27, Preserve Access to Affordable Generics Act
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
General discussions regarding the rauthorization of the Prescription Drug User Fee Act (PDUFA), S. 3187 and H.R. 5651; and education and awareness of vaccine production and infrastructure needs.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues related to changes to the Medicare Part B reimbursement of prescription drugs; issues related to coverage and reimbursement issues for those who are covered by the Medicaid program and the Medicare program; including the Part D prescription drug benefit.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to foreign direct investment in the United States, including all provisions of S. 3274 and H.R. 5910, Global Investment in American Jobs Act of 2012.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Economics/Economic Development
Lobbying Issues
General issues related to prescription drug safety and the importation of prescription drugs. Opposed amendment to PDUFA,
S. 3187, that would allow unsafe importation of drugs.General issues regarding implementation of Public Law 111-148, Patient Protection and Affordable Care Act - including issues related to the Independent Payment Advisory Board.
Issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine.
H.R. 2405 and S.1855, Pandemic and All Hazards Preparation Act Reauthorization of 2011 - all provisions.
H.R. 3627 and S.1884, School Access to Emergency Epinephrine Act - all provisions.
Education and awareness of influenza pandemic and biodefense funding in FY2012 and related international intellectual property issues.
Education and awareness of Dengue.
All provisions of H. Res. 295, Promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with this disease.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2012
In Q3, PARRY, ROMANI, DECONCINI & SYMMS lobbied for sanofi-aventis U.S. Inc. , earning $30,000. The report was filed on Oct. 17, 2012.
Original Filing: 300509535.xml
Lobbying Issues
Opposed efforts to preclude settlements in patent litigation.
H.R. 3995, Protecting Consumer Access to Generic Drugs Act of 2012
S. 27, Preserve Access to Affordable Generics Act
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
General discussions regarding the rauthorization of the Prescription Drug User Fee Act (PDUFA), S. 3187 and H.R. 5651; and education and awareness of vaccine production and infrastructure needs.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues related to changes to the Medicare Part B reimbursement of prescription drugs; issues related to coverage and reimbursement issues for those who are covered by the Medicaid program and the Medicare program; including the Part D prescription drug benefit.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to foreign direct investment in the United States, including all provisions of S. 3274 and H.R. 5910, Global Investment in American Jobs Act of 2012.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Economics/Economic Development
Lobbying Issues
General issues related to prescription drug safety and the importation of prescription drugs. Opposed amendment to PDUFA,
S. 3187, that would allow unsafe importation of drugs.General issues regarding implementation of Public Law 111-148, Patient Protection and Affordable Care Act - including issues related to the Independent Payment Advisory Board and efforts to repeal provisions that prohibit individuals from using Health Savings Accounts or Flexible Spending Accounts to purchase Over-The-Counter medical products, including such provisions in H.R.2529, Restoring Access to Medication Act and H.R.436 - Health Care Cost Reduction Act of 2012.
Awareness and issues related to diabetes and patient access to diabetes care.
H.R.4223, Strengthening and Focusing Enforcement to Deter Organized Stealing and Enhance Safety Act of 2012 or "SAFE DOSES Act" - all provisions.
Issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine.
H.R. 2405 and S.1855, Pandemic and All Hazards Preparation Act Reauthorization of 2011 - all provisions.
H.R. 3627 and S.1884, School Access to Emergency Epinephrine Act - all provisions.
Education and awareness of influenza pandemic and biodefense funding in FY2012 and related international intellectual property issues.
Education and awareness of Dengue.
All provisions of H. Res. 295, Promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with this disease.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2012
In Q2, PARRY, ROMANI, DECONCINI & SYMMS lobbied for sanofi-aventis U.S. Inc. , earning $30,000. The report was filed on July 18, 2012.
Original Filing: 300488043.xml
Lobbying Issues
Opposed efforts to preclude settlements in patent litigation.
H.R. 3995, Protecting Consumer Access to Generic Drugs Act of 2012
S. 27, Preserve Access to Affordable Generics Act
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
General discussions regarding the rauthorization of the Prescription Drug User Fee Act (PDUFA), S. 3187 and H.R. 5651; and education and awareness of vaccine production and infrastructure needs.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues related to changing reimbursement for physicians in the Medicare Part B program and general issues related to changes to the Medicare Part D program.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to foreign direct investment in the United States, including all provisions of S. 3274 and H.R. 5910, Global Investment in American Jobs Act of 2012.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Economics/Economic Development
Lobbying Issues
Support H.R. 3627 and S. 1884, School Access to Emergency Epinephrine Act.
General issues related to prescription drug safety and the importation of prescription drugs. Opposed amendment to PDUFA,
S. 3187, that would allow unsafe importation of drugs.
Agencies Lobbied
U.S. Senate
1st Quarter, 2012
In Q1, PARRY, ROMANI, DECONCINI & SYMMS lobbied for sanofi-aventis U.S. Inc. , earning $30,000. The report was filed on April 17, 2012.
Original Filing: 300462535.xml
Lobbying Issues
Opposed efforts to preclude settlements in patent litigation.
H.R. 3995, Protecting Consumer Access to Generic Drugs Act of 2012
S. 27, Preserve Access to Affordable Generics Act
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
General discussions regarding the rauthorization of the Prescription Drug User Fee Act (PDUFA); and education and awareness of vaccine production and infrastructure needs.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues related to changing reimbursement for physicians in the Medicare Part B program and general issues related to changes to the Medicare Part D program.
Agencies Lobbied
U.S. Senate
4th Quarter, 2011
In Q4, PARRY, ROMANI, DECONCINI & SYMMS lobbied for sanofi-aventis U.S. Inc. , earning $30,000. The report was filed on Jan. 18, 2012.
Original Filing: 300441476.xml
Lobbying Issues
S. 27 - "Preserve Access to Affordable Generics Act"; intellectual property provisions in the pending South Korea, Columbia and Panama Free Trade Agreements; international intellectual property issues. Opposed efforts to preclude settlements in patent litigation.
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Awareness and issues related to patient access to atrial fibrillation care, including all provisions in H. Res. 295 - "Promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with this disease", and S. Res. 243 - "A resolution promoting increased awareness, diagnosis,
and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with this disease".
General issues related to prescription drug safety and the importation of prescription drugs including amendment No. 769 to H.
R. 2112, Consolidated and Further Continuing Appropriations Act, 2012.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General discussions regarding the rauthorization of the Prescription Drug User Fee Act (PDUFA); and education and awareness of vaccine production and infrastructure needs.
H.R. 2112, Continuing Appropriations Act, Opposed amendment No. 769 to prohibit FDA from preventing importation of prescription drugs.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues related to changing reimbursement for physicians in the Medicare Part B program and general issues related to changes to the Medicare Part D program.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2011
In Q3, PARRY, ROMANI, DECONCINI & SYMMS lobbied for sanofi-aventis U.S. Inc. , earning $30,000. The report was filed on Oct. 17, 2011.
Original Filing: 300415738.xml
Lobbying Issues
H.R. 1249/S. 23 - "America Invents Act" provisions related to first to file, inter parties review and supplemental re-examination; issues related to patent settlements, including such provisions in S. 27 - "Preserve Access to Affordable Generics Act"; intellectual property provisions in the pending South Korea, Columbia and Panama Free Trade Agreements; international intellectual property issues.
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Awareness and issues related to patient access to atrial fibrillation care, including all provisions in H. Res. 295 - "Promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with this disease", and S. Res. 243 - "A resolution promoting increased awareness, diagnosis,
and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with this disease".
Agencies Lobbied
U.S. Senate
Lobbying Issues
General discussions regarding the rauthorization of the Prescription Drug User Fee Act (PDUFA); and education and awareness of vaccine production and infrastructure needs.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues related to changing reimbursement for physicians in the Medicare Part B program and general issues related to changes to the Medicare Part D program.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2011
In Q2, PARRY, ROMANI, DECONCINI & SYMMS lobbied for sanofi-aventis U.S. Inc. , earning $30,000. The report was filed on July 13, 2011.
Original Filing: 300389210.xml
Lobbying Issues
Monitor S. 23/H.R. 1249, America Invents Act of 2011. Support amendments to strengthen patent enforcement.
Oppose legislative efforts to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and for other purposes.
Oppose legislation that prohibits settlement agreements between patent litigants that involve anything of value.
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Support H. Res. 295, Promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with this disease.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2011
In Q1, PARRY, ROMANI, DECONCINI & SYMMS lobbied for sanofi-aventis U.S. Inc. , earning $30,000. The report was filed on April 8, 2011.
Original Filing: 300361117.xml
Lobbying Issues
Monitor S. 23/H.R. 1249, America Invents Act of 2011. Support amendments to strengthen patent enforcement.
Oppose legislative efforts to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and for other purposes.
Oppose legislation that prohibits settlement agreements between patent litigants that involve anything of value.
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Oppose legislative efforts to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and for other purposes.
Oppose legislation that prohibits settlement agreements between patent litigants that involve anything of value.
Type of Issue
Law Enforcement/Crime/Criminal Justice
4th Quarter, 2010
In Q4, PARRY, ROMANI, DECONCINI & SYMMS lobbied for sanofi-aventis U.S. Inc. , earning $30,000. The report was filed on Jan. 14, 2011.
Original Filing: 300338293.xml
Lobbying Issues
Monitor S. 515/H.R. 1260, Patent Reform Act of 2009. Support amendments to strengthen patent enforcement.
H.R. 1706/S. 369, Oppose bills that prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and for other purposes. Oppose legislation that prohibits settlement agreements between patent litigants that involve anything of value.
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H.R. 1706/S. 369, To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and for other purposes. Oppose legislation that prohibits settlement agreements between patent litigants that involve anything of value.
Type of Issue
Law Enforcement/Crime/Criminal Justice
3rd Quarter, 2010
In Q3, PARRY, ROMANI, DECONCINI & SYMMS lobbied for sanofi-aventis U.S. Inc. , earning $30,000. The report was filed on Oct. 14, 2010.
Original Filing: 300312829.xml
Lobbying Issues
Monitor S. 515/H.R. 1260, Patent Reform Act of 2009. Support amendments to strengthen patent enforcement.
H.R. 1706/S. 369, Oppose bills that prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and for other purposes. Oppose legislation that prohibits settlement agreements between patent litigants that involve anything of value.
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H.R. 1706/S. 369, To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and for other purposes. Oppose legislation that prohibits settlement agreements between patent litigants that involve anything of value.
Type of Issue
Law Enforcement/Crime/Criminal Justice
2nd Quarter, 2010
In Q2, PARRY, ROMANI, DECONCINI & SYMMS lobbied for sanofi-aventis U.S. Inc. , earning $30,000. The report was filed on July 14, 2010.
Original Filing: 300286271.xml
Lobbying Issues
Monitor S. 515/H.R. 1260, Patent Reform Act of 2009. Support amendments to strengthen patent enforcement.
H.R. 1706/S. 369, Oppose bills that prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and for other purposes. Oppose legislation that prohibits settlement agreements between patent litigants that involve anything of value.
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H.R. 1706/S. 369, To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and for other purposes. Oppose legislation that prohibits settlement agreements between patent litigants that involve anything of value.
Type of Issue
Law Enforcement/Crime/Criminal Justice
1st Quarter, 2010
In Q1, PARRY, ROMANI, DECONCINI & SYMMS lobbied for sanofi-aventis U.S. Inc. , earning $30,000. The report was filed on April 7, 2010.
Original Filing: 300254798.xml
Lobbying Issues
Monitor S. 515/H.R. 1260, Patent Reform Act of 2009. Support amendments to strengthen patent enforcement.
H.R. 1706/S. 369, Oppose bills that prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and for other purposes. Oppose legislation that prohibits settlement agreements between patent litigants that involve anything of value.
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H.R. 1706/S. 369, To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and for other purposes. Oppose legislation that prohibits settlement agreements between patent litigants that involve anything of value.
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
H.R. 3590, The Patient Protection and Affordable Care Act. Oppose provision that prohibits settlement agreements between patent litigants. Monitor Affordable Biologics for Consumers Act and Biologics Price Competition and Innovation Act of 2009, support enactment and follow-on Biologics legislation with amendments that strengthen FDA pathway and provide 12 years data exclusivity.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
H.R. 3590, Patient Protection and Affordable Care Act. Monitor healthcare reform. S.1679, Affordable Health Choices Act (HELP Committee bill); Opposed efforts to add amendments allowing the importation of unsafe drugs from overseas and to prohibit settlements of patent disputes involving anything of value.
4th Quarter, 2009
In Q4, PARRY, ROMANI, DECONCINI & SYMMS lobbied for sanofi-aventis U.S. Inc. , earning $30,000. The report was filed on Jan. 15, 2010.
Original Filing: 300233364.xml
Lobbying Issues
Monitor S. 515/H.R. 1260, Patent Reform Act of 2009. Support amendments to strengthen patent enforcement.
H.R. 1706/S. 369, To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and for other purposes - Oppose legislation that prohibits settlement agreements between patent litigants that involve anything of value.
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H.R. 1706/S. 369, To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and for other purposes - Oppose legislation that prohibits settlement agreements between patent litigants that involve anything of value.
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
H.R. 3590, The Patient Protection and Affordable Care Act. Oppose provision that prohibits settlement agreements between patent litigants. Monitor Affordable Biologics for Consumers Act and Biologics Price Competition and Innovation Act of 2009, support enactment and follow-on Biologics legislation with amendments that strengthen FDA pathway and provide data exclusivity.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
H.R. 3590, Patient Protection and Affordable Care Act. Monitor healthcare reform. S.1679, Affordable Health Choices Act (HELP Committee bill); S. ____, America's Healthy Future Act (not yet introduced); and H.R. 3200, America's Affordable Health Choices Act of 2009.
3rd Quarter, 2009
In Q3, PARRY, ROMANI, DECONCINI & SYMMS lobbied for sanofi-aventis U.S. Inc. , earning $30,000. The report was filed on Oct. 15, 2009.
Original Filing: 300205577.xml
Lobbying Issues
Oppose importation of unsafe drugs from outside the United States.
Monitor S. 515/H.R. 1260, Patent Reform Act of 2009. Support amendments to strengthen patent enforcement.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Monitor legislation reforming the Committee on Foreign Investment in the United States process.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Financial Institutions/Investments/Securities
Lobbying Issues
Monitor legislation regulating agreements between pharmaceutical companies to settle patent infringement lawsuits.
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Monitor Affordable Biologics for Consumers Act and Biologics Price Competition and Innovation Act of 2009, support enactment and follow-on Biologics legislation with amendments that strengthen FDA pathway and provide data exclusivity. (No bill number/legislation introduced yet.)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Monitor healthcare reform. S.1679, Affordable Health Choices Act (HELP Committee bill); S. ____, America's Healthy Future Act (not yet introduced); and H.R. 3200, America's Affordable Health Choices Act of 2009.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2009
In Q2, PARRY, ROMANI, DECONCINI & SYMMS lobbied for sanofi-aventis U.S. Inc. , earning $30,000. The report was filed on July 16, 2009.
Original Filing: 300181356.xml
Lobbying Issues
Oppose importation of unsafe drugs from outside the United States.
Monitor S. 515/H.R. 1260, Patent Reform Act of 2009. Support amendments to strengthen patent enforcement.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Monitor legislation reforming the Committee on Foreign Investment in the United States process.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Financial Institutions/Investments/Securities
Lobbying Issues
Monitor legislation regulating agreements between pharmaceutical companies to settle patent infringement lawsuits.
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Monitor Affordable Biologics for Consumers Act and Biologics Price Competition and Innovation Act of 2007, support enactment and follow-on Biologics legislation with amendments that strengthen FDA pathway and provide data exclusivity.
H.R. 1956 - Patient Protection and Innovative Biologic Medicines Act of 2007.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Monitor healthcare reform. S.____, Affordable Health Choices Act (HELP Committee bill); S. ____, Finance Committee bill not yet introduced; and H.R. _____, America's Affordable Health Choices Act of 2009. (The above bills have not yet been introduced and as such, no bill numbers are available.)
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2009
In Q1, PARRY, ROMANI, DECONCINI & SYMMS lobbied for sanofi-aventis U.S. Inc. , earning $30,000. The report was filed on April 17, 2009.
Original Filing: 300154298.xml
Lobbying Issues
Oppose importation of unsafe drugs from outside the United States.
Monitor S. 515, Patent Law Reform. Support amendments to strengthen patent enforcement.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Monitor legislation reforming the Committee on Foreign Investment in the United States process.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Financial Institutions/Investments/Securities
Lobbying Issues
Monitor legislation regulating agreements between pharmaceutical companies to settle patent infringement lawsuits.
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Monitor Affordable Biologics for Consumers Act and Biologics Price Competition and Innovation Act of 2007, support enactment and follow-on Biologics legislation with amendments that strengthen FDA pathway and provide data exclusivity.
H.R. 1956 - Patient Protection and Innovative Biologic Medicines Act of 2007.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
4th Quarter, 2008
In Q4, PARRY, ROMANI, DECONCINI & SYMMS lobbied for sanofi-aventis U.S. Inc. , earning $30,000. The report was filed on Jan. 17, 2009.
Original Filing: 300125356.xml
Lobbying Issues
Oppose importation of unsafe drugs from outside the United States.
Monitor S. 1145 and H.R. 1082, Patent Law Reform. Support amendments to strengthen patent enforcement.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Monitor legislation reforming the Committee on Foreign Investment in the United States process.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Financial Institutions/Investments/Securities
Lobbying Issues
Monitor legislation regulating agreements between pharmaceutical companies to settle patent infringement lawsuits.
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Support efforts to obtain approval of at least one more compendia by the Department of Health and Human Services for use in Medicare reimbursement decisions for cancer medications. S. 1505 - Affordable Biologics for Consumers Act
S. 1695 Biologics Price Competition and Innovation Act of 2007, support enactment and follow-on Biologics legislation with amendments that strengthen FDA pathway and provide data exclusivity.
H.R. 1956 - Patient Protection and Innovative Biologic Medicines Act of 2007
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2008
In Q3, PARRY, ROMANI, DECONCINI & SYMMS lobbied for sanofi-aventis U.S. Inc. , earning $30,000. The report was filed on Oct. 15, 2008.
Original Filing: 300093527.xml
Lobbying Issues
Oppose importation of unsafe drugs from outside the United States.
Monitor S. 1145 and H.R. 1082, Patent Law Reform. Support amendments to strengthen patent enforcement.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Monitor legislation reforming the Committee on Foreign Investment in the United States process.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Financial Institutions/Investments/Securities
Lobbying Issues
Monitor legislation regulating agreements between pharmaceutical companies to settle patent infringement lawsuits.
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Support efforts to obtain approval of at least one more compendia by the Department of Health and Human Services for use in Medicare reimbursement decisions for cancer medications. S. 1505 - Affordable Biologics for Consumers Act
S. 1695 Biologics Price Competition and Innovation Act of 2007, support enactment and follow-on Biologics legislation with amendments that strengthen FDA pathway and provide data exclusivity.
H.R. 1956 - Patient Protection and Innovative Biologic Medicines Act of 2007
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
2nd Quarter, 2008
In Q2, PARRY, ROMANI, DECONCINI & SYMMS lobbied for sanofi-aventis U.S. Inc. , earning $30,000. The report was filed on July 18, 2008.
Original Filing: 300073596.xml
Lobbying Issues
Oppose importation of unsafe drugs from outside the United States.
Monitor S. 1145 and H.R. 1082, Patent Law Reform. Support amendments to strengthen patent enforcement.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Monitor legislation reforming the Committee on Foreign Investment in the United States process.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Financial Institutions/Investments/Securities
Lobbying Issues
Monitor legislation regulating agreements between pharmaceutical companies to settle patent infringement lawsuits.
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Support efforts to obtain approval of at least one more compendia by the Department of Health and Human Services for use in Medicare reimbursement decisions for cancer medications. S. 1505 - Affordable Biologics for Consumers Act
S. 1695 Biologics Price Competition and Innovation Act of 2007, support enactment and follow-on Biologics legislation with amendments that strengthen FDA pathway and provide data exclusivity.
H.R. 1956 - Patient Protection and Innovative Biologic Medicines Act of 2007
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
1st Quarter, 2008
PARRY, ROMANI, DECONCINI & SYMMS amended a lobbying report for representation of sanofi-aventis U.S. Inc. in Q12008 on April 15, 2008.
Original Filing: 300037646.xml
Lobbying Issues
Oppose importation of unsafe drugs from outside the United States.
Monitor S. 1145 and H.R. 1082, Patent Law Reform. Support amendments to strengthen patent enforcement.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Monitor legislation reforming the Committee on Foreign Investment in the United States process.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Financial Institutions/Investments/Securities
Lobbying Issues
Monitor legislation regulating agreements between pharmaceutical companies to settle patent infringement lawsuits.
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Support efforts to obtain approval of at least one more compendia by the Department of Health and Human Services for use in Medicare reimbursement decisions for cancer medications.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
1st Quarter, 2008
In Q1, PARRY, ROMANI, DECONCINI & SYMMS lobbied for sanofi-aventis U.S. Inc. , earning $40,000. The report was filed on April 7, 2008.
Original Filing: 300033172.xml
Lobbying Issues
Oppose importation of unsafe drugs from outside the United States.
Monitor S. 1145 and H.R. 1082, Patent Law Reform. Support amendments to strengthen patent enforcement.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Monitor legislation reforming the Committee on Foreign Investment in the United States process.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Financial Institutions/Investments/Securities
Lobbying Issues
Monitor legislation regulating agreements between pharmaceutical companies to settle patent infringement lawsuits.
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Support efforts to obtain approval of at least one more compendia by the Department of Health and Human Services for use in Medicare reimbursement decisions for cancer medications.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
4th Quarter, 2007
PARRY, ROMANI, DECONCINI & SYMMS filed a lobbying registration on Dec. 17, 2007 to represent sanofi-aventis U.S. Inc., effective Dec. 18, 2007.
Original Filing: 300001818.xml
Issue(s) they said they’d lobby about: FDA-related legislation; authorized generics/patent and Hatch-Waxman reform; follow-on biogics (biosimilars); manufacturer
pricing or rebate obligations and patient access under govt. programs such as Medicaid & Medicare; military & veterans health
care programs involving prescription meds.; pharmaceutical drug importation; CMS coverage & reimbursement; legal reform issues. .
0th Quarter, 2007
In MM, PARRY, ROMANI, DECONCINI & SYMMS lobbied for SANOFI AVENTIS , earning $80,000. The report was filed on July 31, 2007.
Original Filing: 200043378.xml
Lobbying Issues
Oppose efforts to import unsafe drugs from outside the United States.
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Oppose Amendments to the Drug Price Competition and Patent Term Restoration Act.
Oppose importation of unsafe drugs from outside the United States.Oppose changes in Medicare Prescription law.
Monitor S. 1145 and H.R. 1082, Patent Law Reform. Support amendments to strengthen patent enforcement.
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Monitor legislation regulating agreements between pharmaceutical companies to settle patent infringement lawsuits.
Type of Issue
Law Enforcement/Crime/Criminal Justice
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...